Andrología-Acceso Abierto
Acceso abierto

abstracto

Pentoxifylline associated with other antioxidants (multimodal therapy) in patients with Peyronie's disease. Results of a controlled study

Gianni Paulis, Furio Pirozzi Farina, Giorgio Cavallini, Giovanni De Giorgio, Davide Barletta, Bruno Rovereto, Paolo Turchi, Enrico Conti, Francesco Varvello, Antonio Artegiani, Antonio Vitarelli, Andrea Fabiani, Giuseppe Dachille, Enrico Spera, Stefano Lauretti, Alessandro Papini, Alessandro Palmieri and Tommaso Brancato

Pentoxifylline (PTX) with other antioxidants, in patients with PD enrolled for conservative medical management.

Methods: We conducted a controlled study on 240 patients diagnosed with Peyronie's Disease (PD). We divided two treatment groups, which differed from each other only by the association with PTX injection into the penis. Two groups (A and B) were composed entirely of 160 patients with PD (80 patients for each group): Group A = injectable PTX (penile and perilesional) 100 mg, every two weeks for six months + PTX 400 mg /oral/twice daily + propolis 600 mg /oral/daily + blueberries 160 mg /oral/daily + Vitamin E 600 mg /oral/daily + Diclofenac sodium 4% topical gel /twice daily, for a period of 6 months. Group B = the same therapy of group A but without PTX injection into the penis. Patients who refused treatment, for various reasons, were included in the control group = Group C (80 patients).

Results: In groups A and B after 6 months of treatment a reduction of penile plaque volume of 50.3% and 25.9% respectively was observed, while in group C a mean increase in plaque volume of 131% was observed. Furthermore, in groups A and B the mean decrease in curvature was -11.07° and -4.4° respectively, while in group C a mean increase in curvature =+14.09° was observed. Conclusion: Our results show that multimodal treatment with PTX associated with antioxidants and topical Diclofenac is significantly effective in the treatment of PE. The treatment results obtained in treatment group A are statistically more significant than those obtained in group B. Pentoxifylline is more effective when the treatment program includes both administration routes: oral + perilesional injection.